Robert Scully - Zoetis Independent Director
| ZTS Stock | USD 163.16 0.59 0.36% |
Director
Mr. Robert W. Scully is Independent Director of the Company. Mr. Scully has nearly 35 years of experience in the financial services industry. He served as a member of the Office of the Chairman of Morgan Stanley from 2007 until his retirement in January 2009, where he had previously been CoPresident of the firm, Chairman of global capital markets and Vice Chairman of investment banking. Prior to joining Morgan Stanley in 1996, he served as a Managing Director at Lehman Brothers and at Salomon Brothers Inc. He currently serves on the boards of KKR Co. Inc., a private equity and asset management firm Chubb Limited, a global property and casualty company and UBS Group AG, a global financial services company. Previously, he served as a director of Bank of America Corporationrationration, GMAC Financial Services and MSCI Inc., and as a Public Governor of FINRA, Inc., the Financial Industry Regulatory Authority. Mr. Scully holds a bachelors degree from Princeton University and an MBA from Harvard Business School, where he previously served on its Board of Deans Advisors since 2013.
| Age | 71 |
| Tenure | 12 years |
| Address | 10 Sylvan Way, Parsippany, NJ, United States, 07054 |
| Phone | 973 822 7000 |
| Web | https://www.zoetis.com |
Zoetis Management Efficiency
The company has Return on Asset of 0.1487 % which means that on every $100 spent on assets, it made $0.1487 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.5114 %, implying that it generated $0.5114 on every 100 dollars invested. Zoetis' management efficiency ratios could be used to measure how well Zoetis manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Zoetis' Return On Capital Employed is comparatively stable compared to the past year. Return On Assets is likely to gain to 0.18 in 2025, whereas Return On Tangible Assets are likely to drop 0.12 in 2025. At this time, Zoetis' Non Currrent Assets Other are comparatively stable compared to the past year. Intangible Assets is likely to gain to about 1.4 B in 2025, whereas Non Current Assets Total are likely to drop slightly above 5.9 B in 2025.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| George Joulwan | Emergent Biosolutions | 80 | |
| Kathryn Zoon | Emergent Biosolutions | 71 | |
| Richard Schutter | Bausch Health Companies | 79 | |
| Robert Power | Bausch Health Companies | 63 | |
| Heather Mason | Assertio Therapeutics | 64 | |
| Art Garcia | Elanco Animal Health | 59 | |
| Carl McMillian | Elanco Animal Health | 53 | |
| Sarah Kavanagh | Bausch Health Companies | 63 | |
| Faysal Kalmoua | Alvotech | 49 | |
| Sue Bailey | Emergent Biosolutions | 76 | |
| Gerald Lieberman | Teva Pharma Industries | 73 | |
| William Doyle | Elanco Animal Health | 58 | |
| Michael Harrington | Elanco Animal Health | 58 | |
| Jerome Hauer | Emergent Biosolutions | 68 | |
| John Paulson | Bausch Health Companies | 64 | |
| Kirk McDonald | Elanco Animal Health | 54 | |
| Roberto Mignone | Teva Pharma Industries | 48 | |
| Shiro Kuniya | Takeda Pharmaceutical Co | 63 | |
| Perry Nisen | Teva Pharma Industries | 64 | |
| Lawrence Kurzius | Elanco Animal Health | 63 | |
| Costa Saroukos | Takeda Pharmaceutical Co | 49 | |
Management Performance
| Return On Equity | 0.51 | ||||
| Return On Asset | 0.15 |
Zoetis Inc Leadership Team
Elected by the shareholders, the Zoetis' board of directors comprises two types of representatives: Zoetis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Zoetis. The board's role is to monitor Zoetis' management team and ensure that shareholders' interests are well served. Zoetis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Zoetis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Roman Trawicki, Executive Vice President and Presidentident of Global Manufacturing and Supply | ||
| Steven Frank, Vice Relations | ||
| Kristin Peck, Chief Executive Officer, Executive Vice President and Group President, U.S. Operations, Business Development and Strategy, Director | ||
| Wafaa Mamilli, Executive Vice President and Chief Information and Digital Officer | ||
| William Steere, Independent Director | ||
| Roxanne Lagano, Chief Human Resource Officer, Executive Vice President and Global Operations | ||
| Linda Rhodes, Independent Director | ||
| Timothy Bettington, Executive Vice President and President U.S. Operations | ||
| Ester Banque, Executive Operations | ||
| Frank DAmelio, Independent Director | ||
| Robert Scully, Independent Director | ||
| Sherry Pudloski, Executive Vice President - Corporate Affairs and Communications | ||
| Sanjay Khosla, Independent Director | ||
| William Price, VP Officer | ||
| Jamie Brannan, Executive Diagnostics | ||
| Catherine Knupp, Executive Vice President, President - Research and Development | ||
| Jeannette Astorga, Executive Officer | ||
| Michael McCallister, Non-Executive Independent Chairman of the Board | ||
| Wetteny CPA, Executive CFO | ||
| Paul Bisaro, Independent Director | ||
| Antoinette Leatherberry, Independent Director | ||
| Nick Ashton, Executive Supply | ||
| Willie Reed, Independent Director | ||
| William Dorsey, Vice Diagnostics | ||
| Rimma Driscoll, Commercial Strategy | ||
| Glenn David, Chief Financial Officer, Executive Vice President | ||
| Wetteny Joseph, Chief Financial Officer, Executive Vice President, Head of Business Development | ||
| Robert Kelly, Executive Vice President and President International Operations | ||
| J McFarland, Executive Vice President and Chief Medical Officer | ||
| Keith Sarbaugh, Executive Officer | ||
| Robert Polzer, Executive Vice President and Presidentident of Research and Development | ||
| Gregory Norden, Independent Director | ||
| Louise Parent, Independent Director | ||
| Heidi Chen, Executive Vice President General Counsel, Corporate Secretary | ||
| Abhay Nayak, Executive Vice President Head of Strategy and Accelerated Growth Businesses | ||
| Julie Fuller, Chief VP | ||
| Juan Alaix, Chief Executive Officer, Director |
Zoetis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Zoetis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.51 | ||||
| Return On Asset | 0.15 | ||||
| Profit Margin | 0.27 % | ||||
| Operating Margin | 0.33 % | ||||
| Current Valuation | 78.08 B | ||||
| Shares Outstanding | 447.79 M | ||||
| Shares Owned By Insiders | 0.20 % | ||||
| Shares Owned By Institutions | 95.66 % | ||||
| Number Of Shares Shorted | 6.51 M | ||||
| Price To Earning | 43.89 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Zoetis Stock Analysis
When running Zoetis' price analysis, check to measure Zoetis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zoetis is operating at the current time. Most of Zoetis' value examination focuses on studying past and present price action to predict the probability of Zoetis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zoetis' price. Additionally, you may evaluate how the addition of Zoetis to your portfolios can decrease your overall portfolio volatility.